Polar Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Polar Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-75,000	Closed	-$2.48M	–	301
2019 Q2	$2.48M	Hold	75,000	–	–	0.02%	252
2019 Q1	$2.63M	Buy	+75,000	New	+$2.79M	0.02%	236
2018 Q4	–	Sell	-75,000	Closed	-$3.78M	–	286
2018 Q3	$3.78M	Sell	75,000 -175,000	-70%	-$8.64M	0.03%	226
2018 Q2	$15K	Sell	250,000 -25,000	-9%	-$1.3M	0.09%	171
2018 Q1	$12.6M	Buy	275,000 +75,000	+38%	+$3.13M	0.13%	169
2017 Q4	$7.97M	Sell	200,000 -138,956	-41%	-$5.49M	0.08%	179
2017 Q3	$13.6M	Buy	338,956 +218,956	+182%	+$9.48M	0.15%	147
2017 Q2	$5.17M	Sell	120,000 -405,000	-77%	-$14.4M	0.07%	188
2017 Q1	$16.4M	Buy	525,000 +370,000	+239%	+$9.92M	0.25%	122
2016 Q4	$3.91M	Buy	155,000 +77,500	+100%	+$1.73M	0.06%	205
2016 Q3	$1.92M	Sell	77,500 -33,025	-30%	-$747K	0.03%	222
2016 Q2	$2.25M	Sell	110,525 -11,561	-9%	-$205K	0.04%	218
2016 Q1	$1.86M	Buy	122,086 +16,065	+15%	+$210K	0.04%	214
2015 Q4	$1.43M	Sell	106,021 -48,922	-32%	-$757K	0.03%	231
2015 Q3	$2.17M	Buy	154,943 +13,869	+10%	+$258K	0.04%	216
2015 Q2	$2.4M	Buy	141,074 +29,401	+26%	+$418K	0.05%	219
2015 Q1	$1.35M	Buy	111,673 +79,245	+244%	+$749K	0.03%	243
2014 Q4	$269K	Buy	+32,428	New	+$272K	0.01%	268

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Polar Capital's SUPN Position: Q3 2019 in Review

Polar Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 75,000 shares — an estimated $2.48M sold.

Polar Capital first reported a position in SUPN in Q4 2014 and held it in 18 quarters. The position peaked at $16.4M in Q1 2017. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Polar Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Polar Capital sold 75,000 Supernus Pharmaceuticals shares in Q3 2019, an estimated $2.48M.
Polar Capital first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 18 quarters.
Polar Capital's Supernus Pharmaceuticals position peaked at $16.4M in Q1 2017.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Polar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.